Skip to main content
Premium Trial:

Request an Annual Quote

Pathwork Dx Inks Deal with Kindstar to Offer Tissue of Origin Test in China

NEW YORK (GenomeWeb News) – Pathwork Diagnostics today announced a deal to offer its Pathwork Tissue of Origin Test for cancer diagnosis in China.

The deal with Kindstar Global, which claims to be the largest esoteric diagnostic testing business in China, expands the Redwood City, Calif.-based company's international network of test and service providers, Pathwork said. The agreement is the first international in vitro diagnostic deal for the company, it added.

Kindstar will offer the IVD kit version of the Tissue of Origin Test, which is cleared by the US Food and Drug Administration and covered by Medicare.

The molecular diagnostic test uses a tumor's genomic information to help clinicians diagnose difficult cancers, such as those that are metastatic or have a complex clinical history, Pathwork said. It measures gene expression levels of 2,000 genes, and by using proprietary algorithms compares the tumor's gene expression pattern to that of 15 tumor types, representing 58 morphologies and 90 percent of all solid tumors.

"Having access to this test will allow us to expand the current testing services we offer Chinese physicians and position our business as the leading diagnostic company in the fastest growing market in the world," Kindstar Founder and CEO Shiang Huang said in a statement.

Financial and other terms of the deal were not disclosed.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.